Clinical trial · Observational
Blood Biomarker Signature in Glioma
Are Gliomas in Adults Associated With a Unique Identifying Blood Biomarker Signature?
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): As per the HRBs new funding model, HRBs investment will not support costs associated with routine patient care or translational studies, biobanks, patient registries and questionnaires. Therefore, a decision was made to cease further study follow up.
Summary
Brief summary (as posted)
This is an exploratory, translational and non-interventional clinical study. The aim of this study is to identify a blood biomarker signature for glioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma of Brain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-interventional | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Cohort 1 / High grade Glioma
- description
- Cohort 1: 1. Histologically confirmed high grade glioma (grade III) or glioblastoma (GBM, astrocytoma grade IV) 2. Planned treatment (RT alone or Chemotherapy alone or a combination of RT/Chemotherapy)
- interventionNames
- Other: Non-interventional
- label
- Cohort 2 / Low grade Glioma
- description
- Cohort 2: 1. Histologically confirmed low grade (grade II) glioma 2. Planned treatment either * expectant monitoring or * RT alone or * Chemotherapy alone or * a combination of RT/Chemotherapy
- interventionNames
- Other: Non-interventional
Primary outcomes (1)
- measure
- Identification of protein and miRNA biomarker ignatures
- timeFrame
- 5 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. All patients with suspected newly diagnosed glioma (grade 2 or 3 or glioblastoma) with planned surgical intervention (resection or biopsy). 2. Patient aged 18 years or older 3. Patients have to be able to give informed consent Exclusion Criteria: 1. Prior Radiotherapy to the central nervous system 2. Prior Chemotherapy within the last 5 years 3. Any prior central nervous system malignancy
References
Publications (0)
Data not yet available